A PHASE 2, OPEN-LABEL, SINGLE-ARM, PROSPECTIVE, MULTICENTER STUDY OF NAB-SIROLIMUS PLUS LETROZOLE IN ADVANCED OR RECURRENT ENDOMETRIOID ENDOMETRIAL CANCER

被引：0

作者：

Dockery, Lauren ^{[1
]}

Musa, Fernanda ^{[2
]}

Mathews, Cara ^{[3
]}

Spirtos, Nick ^{[4
]}

Slomovitz, Brian ^{[5
,6
]}

Priebe, Anna ^{[7
]}

Green, Angela ^{[8
]}

Puechl, Allison ^{[9
]}

Birrer, Michael ^{[10
]}

Herzog, Thomas ^{[11
]}

Ding, Li ^{[12
]}

Schmid, Anita ^{[12
]}

Navarro, Willis ^{[12
]}

Moore, Kathleen ^{[13
]}

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK 73104 USA

[2] Swedish Canc Inst, Seattle, WA USA

[3] Women & Infants Hosp Rhode Isl, Providence, RI USA

[4] Womens Canc Ctr Nevada, Las Vegas, NV USA

[5] Florida Int Univ, Mt Sinai Med Ctr, Dept Gynecol Oncol, Miami Beach, FL USA

[6] Florida Int Univ, Dept Obstet & Gynecol, Miami Beach, FL USA

[7] Texas Oncol, Ft Worth, TX USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY USA

[9] Atrium Hlth, Charlotte, NC USA

[10] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Little Rock, AR USA

[11] Univ Cincinnati, Canc Ctr, Cincinnati, OH USA

[12] Aadi Biosci, Pacific Palisades, CA USA

[13] Oklahoma Univ Hlth, Stephenson Canc Ctr, Oklahoma City, OK USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期

关键词：

D O I：

10.1136/ijgc-2024-IGCS.606

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TP004/#156

引用

页码：A348 / A348

页数：1

共 50 条

[1] A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Dockery, Lauren E.
Slomovitz, Brian M.
Musa, Fernanda
Mathews, Cara Amanda
Priebe, Anna M.
Green, Angela
Puechl, Allison
Birrer, Michael J.
Spirtos, Nicola M.
Ding, Li
Schmid, Anita N.
Navarro, Willis H.
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] A phase 2, open-label, single-arm, prospective, multi-center study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Dockery, Lauren
Priebe, Anna
Duska, Linda
Green, Angela
Mathews, Cara
Musa, Fernanda
O'Malley, David
Puechl, Allison
Ding, Li
Schmid, Anita
Navarro, Willis
Slomovitz, Brian
Moore, Kathleen
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A249 - A250
[3] A phase 2, openlabel, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Dockery, Lauren E.
Priebe, Anna
Duska, Linda
Green, Angela K.
Mathews, Cara
Musa, Fernanda
O'Malley, David
Puechl, Allison
Ding, Li
Schmid, Anita N.
Navarro, Willis H.
Slomovitz, Brian
Moore, Kathleen
CLINICAL CANCER RESEARCH, 2024, 30 (05)
[4] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
Wei, W.
Ban, X.
Yang, F.
Huang, Y.
Li, J.
Cheng, X.
Zheng, M.
Li, J.
ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
[5] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
Wei, Wei
Ban, Xiaohua
Yang, Fan
Huang, Yongwen
Li, Jibin
Qiu, Ya
Cheng, Xiaqin
Li, Jundong
Zheng, Min
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Anlotinib plus letrozole in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study.
Wang, Xipeng
Li, Jiarui
Zhang, Ping
Fang, Xuhong
Wang, Yizhi
Sun, Huizhen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17545 - E17545
[7] A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
Li, G.
Zhao, Y.
Jiang, Y.
Yang, Q.
Huang, A.
Chen, Y.
Han, D.
ANNALS OF ONCOLOGY, 2021, 32 : S753 - S754
[8] Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial
Ozeki, Michio
Endo, Saori
Yasue, Shiho
Nozawa, Akifumi
Asada, Ryuta
Saito, Akiko M.
Hashimoto, Hiroya
Fujimura, Takumi
Yamada, Yohei
Kuroda, Tatsuo
Ueno, Shigeru
Watanabe, Shoji
Nosaka, Shunsuke
Miyasaka, Mikiko
Umezawa, Akihiro
Matsuoka, Kentaro
Maekawa, Takanobu
Hirakawa, Satoshi
Furukawa, Taizo
Fumino, Shigehisa
Tajiri, Tatsuro
Takemoto, Junkichi
Souzaki, Ryota
Kinoshita, Yoshiaki
Fujino, Akihiro
FRONTIERS IN MEDICINE, 2024, 11
[9] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Makker, Vicky
Rasco, Drew
Vogelzang, Nicholas J.
Brose, Marcia S.
Cohn, Allen L.
Mier, James
Di Simone, Christopher
Hyman, David M.
Stepan, Daniel E.
Dutcus, Corina E.
Schmidt, Emmett V.
Guo, Matthew
Sachdev, Pallavi
Shumaker, Robert
Aghajanian, Carol
Taylor, Matthew
LANCET ONCOLOGY, 2019, 20 (05): : 711 - 718
[10] Sirolimus Treatment for Intractable Vascular Anomalies: An Interim Analysis of an Open-Label, Single-Arm, Multicenter, Prospective Study
Ozeki, Michio
Nozawa, Akifumi
Yasue, Shiho
Endo, Saori
Asada, Ryuta
Hashimoto, Hiroya
Sozaki, Ryota
Fumino, Shigehisa
Furukawa, Taizo
Tajiri, Tatsuro
Fukao, Toshiyuki
PEDIATRIC BLOOD & CANCER, 2019, 66 : S5 - S5

← 1 2 3 4 5 →